Based on the findings that miR-223 could directly target NLRP342,48, and suppress NLRP3 inflammasome and IL-18 production in our study, miR-223-based therapeutic may hold promise as future novel therapeutics for AOSD. This evidence concerns the gene NLRP3 and adult-onset Still disease.